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Neuroimmune interactions underlying the development of pain sensitization in models of neuropathic 
pain have been widely studied. In this study, we evaluated the development of allodynia and its 
reduction associated with peripheral antineuroinflammatory effects induced by a dexamethasone-loaded 
biodegradable implant. Chronic constriction injury (CCI) of the sciatic nerve was performed in Wistar 
rats. The electronic von Frey test was applied to assess mechanical allodynia. The dexamethasone-loaded 
implant was placed perineurally at the moment of CCI or 12 days after surgery. Dorsal root ganglia (DRG; 
L4-L5) were harvested and nuclear extracts were assayed by Western blot for detection of nuclear factor 
(NF)-κB p65/RelA translocation. Dexamethasone delivered from the implant delayed the development 
of allodynia for approximately three weeks in CCI rats when the implantation was performed at day 0, 
but allodynia was not reversed when the implantation was performed at day 12. NF-κB was activated in 
CCI rat DRG compared with naïve or sham animals (day 15), and dexamethasone implant inhibited p65/
RelA translocation in CCI rats compared with control. This study demonstrated that the dexamethasone-
loaded implant suppresses allodynia development and peripheral neuroinflammation. This device can 
reduce the potential side effects associated with oral anti-inflammatory drugs. 
Keywords: Chronic Constriction Injury. Dexamethasone/ pharmacology. Delivery device. Neuropathic 
Pain/ chemically induced. Nuclear Factor kappa B/ drug effects. Neuralgia/ chemically induced. NF-
kappa B/ drug effects. Sciatic Nerve/ injuries. Absorbable Implants/ trends.
INTRODUCTION
Dexamethasone, a potent anti-inflammatory and 
immunosuppressant drug, inhibits fibrovascular tissue 
formation around sutures, infiltration of inflammatory 
cells, and thermal hyperalgesia when administered 
intraperitoneally before and after chronic constriction 
injury (CCI) in rats (Clatworthy et al., 1995). It is 
tempting to associate the antiallodynic effect induced 
by a steroidal anti-inflammatory drug (SAID) with its 
anti-inflammatory actions on the peripheral nervous 
system. When rats with CCI have the sciatic nerves 
re-exposed and treated locally with a depot form of 
methylprednisolone at day 10 after injury, antiallodynic 
and antihyperalgesic effects are observed up to day 21 
(Johansson, Bennett, 1997), thus providing evidence 
that SAIDs may act locally at the site of nerve injury to 
inhibit sensitization. On the other hand, spinally applied 
dexamethasone induces pro-nociceptive effects after 
peripheral nerve injury (Wang et al., 2004).
Immune activation and the subsequent release 
of immune mediators in the peripheral nervous system 
contribute to pain. A variety of peripheral immune cells, 
including mast cells, macrophages, and lymphocytes, 
are resident in nerves and/or recruited to sites of 
peripheral nerve injury. These cells produce a plethora of 
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inflammatory mediators that sensitize or directly activate 
peripheral neurons to generate action potentials, leading 
to peripheral and central sensitization. The peripheral and 
central sensitization contributes to the development of 
allodynia and hyperalgesia, two hallmarks of neuropathic 
painful states (McMahon, Cafferty, Marchand, 2005; 
Perkins, Tracey, 2000). Proliferation of satellite cells 
occurs in dorsal root ganglia (DRGs), as well as infiltration 
of macrophages and T cells to this site (McMahon, 
Cafferty, Marchand, 2005). Different kinds of sciatic nerve 
injury lead to activation of nuclear factor κB (NF-κB) in 
DRGs (Ma, Bisby, 1998). In non-stimulated cells, NF-κB 
consists of a heterodimer of subunits p50 and p65 that 
form a complex with IκB, an inhibitory protein. Several 
endogenous or exogenous molecules can activate NF-κB, 
mainly the heterodimers p65RelA/p50, which translocate 
to the nucleus, thereby modulating the expression of 
pro-inflammatory genes, such as those for inducible 
nitric oxide synthase, cyclo-oxygenase-2, adhesion 
molecules, cytokines, and chemokines (Kaltschmidt, 
Widera, Kaltschmidt, 2005). NF-κB plays an essential 
role in the gene expression of inflammatory mediators 
in neurons and glial cells, besides many other cell types. 
Transgenic inhibition of glial NF-κB inhibits hyperalgesia 
and allodynia in mice, and these effects are associated 
with reduced cytokine/chemokine production in DRGs 
(Fu et al., 2010).
To further study the peripheral antineuroinflammatory 
actions of SAIDs, in the present study we investigated the 
ability of a dexamethasone-loaded biodegradable implant 
to prevent the mechanical allodynia induced by sciatic 
injury in rats and its possible association with an effect 
on NF-κB activation in DRG. Biodegradable implants 
may be an effective dosage form since they may promote 
a controlled drug release at therapeutic levels for a 
prolonged period of time without frequent doses, avoiding 
undesirable targeting of healthy tissues and harmful side 
effects, as lower concentrations of drugs are administered 
when compared to oral formulations (Dash, Cudworth 
2nd., 1998; Langer, 1998).
MATERIAL AND METHODS
Dexamethasone was purchased from Sigma-Aldrich 
(Brazil). Poly-lactide-co-glycolide copolymer (PLGA 
50:50, PURASORB® PDLG 5004, inherent viscosity 
midpoint of 0.4 dl/g) was a gift from Purac Biomaterials 
(Brazil). Acetonitrile HPLC grade was purchased from 
Merck Brasil (Brazil). Ultrapure water was obtained from 
Milli-Q, Millipore (USA). All other chemicals were of 
analytical grade.
Preparation of dexamethasone-loaded 
biodegradable implants
The implants were prepared according to the 
technique previously described by Fialho, Silva-Cunha 
(2005). Dexamethasone and the polymer PLGA 50:50 
at a ratio 1:4 were dissolved in a mixture of distilled 
water and acetonitrile and the resulting solution was 
lyophilized (-40 °C, Pirani501 78/L, Edwards Ltda., 
Brazil). The powder obtained was molded into rods 
using a hot plate. The implants weighed on average 6.0 
± 0.1 mg, were 4.0 ± 0.1 mm in length, and 1.0 ± 0.05 
mm in diameter (Figure 1). The final concentration of 
dexamethasone dispersed in the polymeric matrix was 
40% w/w. Implants without drug were also prepared 
using the same technique.
Animals
All experiments were performed according to the 
ethical guidelines for the investigation of experimental 
pain in conscious animals and to the EU Directive 
2010/63/EU for animal experiments.  The study 
was approved by the Ethics Committee on Animal 
Experimentation of the Federal University of Minas Gerais 
(Protocol 168/2009). 
Male Wistar rats (240–280 g) were used, with groups 
matched on body mass (approximately 260 g on average). 
The animals had free access to food and water and were 
maintained in a room with a 12 h light-dark cycle for 
3 d before the experiment to allow for acclimatization. 
For three consecutive days before the experiment, the 
animals were habituated for approximately 30 min to the 
testing apparatuses in order to minimize stress-induced 
FIGURE 1 - Dexamethasone-loaded PLGA implant (weight: 
6.0 ± 0.1mg; length: 4.0 ± 0.1 mm; diameter: 1.0 ± 0.05 mm).
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antinociception. The investigator performing behavioral 
tests was blinded to all treatments. 
Surgery and drugs
Chronic constriction injury (CCI) of the right sciatic 
nerve was performed as previously described by Bennett, 
Xie (1988), under anesthesia induced by ketamine 
(90 mg/kg) and xylazine (9 mg/kg) hydrochlorides 
(both manufactured by Vetbrands; Paulínia, São Paulo, 
Brazil). Four ligatures with a flexible nylon thread were 
tied loosely around the sciatic nerve at mid-thigh level 
(Motta et al., 2011). Sham-operated animals underwent 
the same surgical procedure, save that the sciatic was not 
ligated. Dexamethasone-loaded PLGA implants or PLGA-
only implants were placed perineurally at the moment of 
CCI or after re-exposure of the sciatic (under anesthesia) 
at day 12 after surgery. 
Electronic von Frey test for mechanical allodynia
Rats were placed in acrylic cages with wire mesh 
floors 15 min before the start of testing. The test consisted 
of evoking a hind paw flexion reflex with a hand-held force 
transducer (electronic pressure-meter, Insight, Ribeirão 
Preto, Brazil) adapted to a 0.5-mm2 polypropylene tip. The 
experimenter was trained to apply the tip perpendicularly 
to the central area of the hind paw with a gradual increase 
in pressure. The endpoint was characterized by the removal 
of the paw usually followed by flinching movements. 
After the paw withdrawal, the intensity of the pressure 
was automatically recorded. The mean withdrawal 
threshold was obtained by averaging 5 measurements. 
The animals were tested before and after surgeries and/
or treatments. The results are expressed by the absolute 
withdrawal threshold (in grams). These procedures were 
done similarly to those previously described elsewhere 
(Vivancos et al., 2004).
NF-κB translocation evaluation
NF-κB translocation was investigated by Western 
blotting analysis of nuclear cell extracts obtained from 
homogenized DRGs, as described elsewhere (Souza et al., 
2009). Ipsilateral L4 and L5 DRGs were harvested and 
immediately frozen in liquid nitrogen. Briefly, the tissue 
was homogenized in ice-cold hypotonic lysis buffer 
(10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.002% 
NaN3, 1 mM PMSF, 0.1 mM EGTA, 10 μM aprotinin, 
20 μM leupeptine, 0.5 mM DTT, 25 mM NaF) and then 
homogenized for approximately 1 min. Next, the same 
buffer was added (500 µL) and the suspension was shaken 
in a vortex. The tissue was kept on ice for 15 min. Next, 
Triton® X-100 (5%) was added and the mixture was 
inverted gently three times and kept on ice for 5 min. 
Centrifugation was performed (6000 rpm, 6 min, 4 ºC) 
and the supernatant containing the cytoplasmic protein 
extract was discarded. The remaining pellet was washed 
out with RSB 1X buffer and centrifuged (9000 rpm, 6 min, 
4 ºC). The supernatant was carefully removed to ensure 
the cytoplasmic extract separation and then the nuclear 
extract was re-suspended in 100 μL buffer C (20 mM 
HEPES pH 7.4, 420 mM NaCl, 1.5 mM MgCl2, 0.01% 
NaN3, 0.2 mM EDTA, 25% v/v glycerol, 1 mM PMSF, 
10 mM aprotinin, 20 mM leupeptin, 0.5 mM DTT). This 
suspension was kept on ice for 45 min, a period during 
which the liquid was shaken in a vortex for 15 s every 5 
min. Afterwards, centrifugation was performed and the 
supernatant was stored at -70 ºC for Western blot analysis. 
Nuclear extracts contents were determined by the Bradford 
method, using the Bio-Rad Protein Assay Kit (Bio-Rad 
Laboratories, Hercules, CA, USA). For immunoblotting, 
15 μg of protein from each sample was subjected to SDS-
polyacrylamide gel electrophoresis on a 10% gel. Primary 
antibodies were anti-p65/RelA (Santa Cruz Biotechnology, 
Dallas, TX, USA; catalog # sc-372; dilution 1:1000) and 
anti-β-actin (Sigma-Aldrich, Saint Louis, MO, USA; 
catalog # A5316; dilution 1:5000), both diluted in PBS/
Tween and bovine serum albumin (5%). Proteins were 
detected with horseradish peroxidase (HRP)-coupled 
goat antirabbit immunoglobulin G or HRP-coupled goat 
antimouse (sc-2357 and sc-2005, respectively; both 
diluted 1:3000 in PBS/Tween and 5% skim milk), using 
chemiluminescence reagents (GE Healthcare, Piscataway, 
NJ, USA).
Percentage of dexamethasone released from the 
implants
The amount of dexamethasone released from the 
implants was calculated indirectly from the retrieved 
implants by high performance liquid chromatography. 
The implants were withdrawn at day 15 after 
constriction injury, gently washed with distilled water, 
and then dissolved in a fixed volume of acetonitrile. 
The amount of dexamethasone was measured by 
high-performance liquid chromatography using the 
method described in the United States Pharmacopeia 
with a Waters apparatus equipped with an autosampler 
model 717 plus (Waters, Milford, MA, USA). A pump 
(model 515; Waters) was used at a constant low rate of 
1.2 mL/min. A C-18 reverse-phase column (3.9 × 150 mm) 
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filled with octadecylsilane chemically bonded to porous 
silica (5 µm, Nova-Pak; Waters) was used. The mobile 
phase was a mixture of acetonitrile and ultra-filtrated water 
(45:55). An ultraviolet detector (model 2487; Waters) was 
used (wavelength: 254 nm). The validation of the method 
showed the absence of interference of the polymer with the 
drug retention time, ruling out the risks of overestimation.
Statistical analyses
The number of animals used in each protocol was 
based on the mathematical relationship between the 
values of the studied effect, standard deviation, level of 
significance and the statistical test power. The behavioral 
and body mass results, expressed as mean ± standard 
error of the mean, were analyzed by two-way repeated 
measures ANOVA followed by Bonferroni post hoc test, 
taking treatment and time as main effects (Figures 2 and 3). 
ImageJ 1.46r (NIH, USA) was used to semiquantitatively 
analyze the immunoblots, which were normalized to 
β-actin. ANOVA followed by Newman-Keuls post hoc 
test or t test was used for comparisons of densitometric 
values (Figure 4). Values of p < 0.05 were considered to 
show significant differences between means. The software 
Prism® 5 (GraphPad Software Inc., San Diego, CA, USA) 
was used for the analyses. 
RESULTS
The perineural implant of dexamethasone delayed 
the development of allodynia when the implantation was 
performed simultaneously to CCI (i.e., at day 0; Figure 2A) 
in rats, but not when the implantation was performed at day 
12 (Figure 2B), when the allodynia was fully established. 
The percentage of dexamethasone release from the 
implants, assessed 15 days after implantation, was 66.4%, 
i.e., approximately 1.6 mg. 
Dexamethasone implantations, performed either at 
day 0 or day 12, prevented body mass gain (Figures 3A 
and 3B, respectively), indicating that dexamethasone had 
been released and had induced its long-known catabolic 
effect (Bullock et al., 1972).
As  expec ted ,  CCI  upregu la ted  p65 /RelA 
translocation in DRG cells (Figures 4A and 4B). Taking 
into account the importance of NF-κB for the expression of 
several inflammatory mediators and the well-known effects 
induced by SAIDs on NF-κB activation, we investigated 
the association between the prevention of allodynia 
development and peripheral antineuroinflammatory effect. 
Indeed, in rats subjected to dexamethasone implantation 
(2.4 mg) at the moment of constriction, we observed 
reduced translocation of NF-κB in comparison with 
vehicle (PLGA)-treated rats (Figures 4C and 4D).
DISCUSSION
In the present study, we showed that a perineural 
implant containing dexamethasone, placed at the 
moment of CCI, delays the development of mechanical 
allodynia in rats. However, such an effect is not observed 
if the nerve is re-exposed at day 12 after surgery and the 
implantation is performed at this time, when allodynia 
is fully established. The delay in allodynia development 
is associated with inhibition of activation of NF-κB in 
FIGURE 2 - Effect induced by dexamethasone (perineural implant containing 2.4 mg, at day 0 (A) or day 12 (B) after constriction 
of sciatic nerve) on the development of mechanical allodynia in rats. BL: baseline. * statistical difference in comparison with the 
CCI vehicle (PLGA)-treated group, as revealed by two-way ANOVA followed by Bonferroni post hoc test. (A) Effect of treatment: 
F(1,224) = 26.11, p < 0.001; effect of time: F(14,224) = 3.81, p < 0.001; interaction: F(14,224) = 2.54, p = 0.0022). Sham-operated 
rats were not affected by treatments (all p values higher than 0.05). (B) All p values higher than 0.05 as well. n = 6-7.
Delay of neuropathic pain sensitization after application of dexamethasone-loaded implant in sciatic nerve-injured rats
Braz. J. Pharm. Sci. 2019;55:e18112 Page 5 / 7
DRG cells – a peripheral antineuroinflammatory effect. 
As the dexamethasone implant was placed closely to 
the CCI site, a local effect is not unlikely and may have 
contributed to its antiallodynic activity. However, as the 
perineural dexamethasone implant prevented body mass 
gain in rats, a systemic effect induced by this drug is 
evident, thus confirming its well-known catabolic activity 
(Bullock et al., 1972) and indicating that effects distant 
from the site of CCI must also be considered when trying 
to explain the antiallodynic activity of this steroid.
A previous study showed that the implantation 
of a depot form of methylprednisolone (2 mg, as 
acetate) perineurally at day 10 after CCI reverses both 
mechanical allodynia and thermal hyperalgesia in rats 
FIGURE 3 - Effect induced by dexamethasone (perineural implant containing 2.4 mg, at day 0 (A) or day 12 (B) after constriction 
of sciatic nerve) on the body mass gain in rats. * statistical difference in comparison with the CCI vehicle (PLGA)-treated group, 
as revealed by two-way ANOVA followed by Bonferroni post hoc test. (A) Effect of treatment: F(1,80) = 11.25, p < 0.004; effect 
of time: F(5,80) = 50.96, p = 0.0001); interaction: F(5,80) = 26.00, p < 0.0001. (B) Effect of treatment: F(1,10) = 5.88, p < 0.0357; 
effect of time: F(1,10) = 17.26, p < 0.002; interaction: F(1,10) = 36.67, p = 0.0001). n = 6-9.
FIGURE 4 - (A and B) Effect induced by chronic constriction injury on the activation of NF-κB in L4-L5 DRG cells (nuclear 
extract protein content) at day 15 after constriction of sciatic nerve. (C and D) Effect induced by dexamethasone (perineural 
implant containing 2.4 mg, at the moment of constriction, i.e., day 0) on the NF-κB activation. (A and C) Immunoblots. (B and D) 
Densitometric analysis of corresponding immunoblots. # statistical difference in comparison with the groups naïve and sham (B; p 
< 0.05), as revealed by ANOVA followed by Newman-Keuls post hoc test. (D) * statistical difference between the two groups (p 
< 0.05), as revealed by t student test. n = 4.
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(Johansson, Bennett, 1997). The authors of that study 
hypothesized that the methylprednisolone treatment 
reduced the hyperexcitability of injured nerve fibers, as a 
previous study had shown that local methylprednisolone 
application blocks transmission in normal nociceptive 
C-fibers (Johansson, Hao, Sjolund, 1990). In vitro studies 
also suggest dexamethasone’s direct actions on neural 
excitability (Borski, 2000). Local administration of 
triamcinolone, another SAID, to ferret lingual nerve at the 
time of injury reduces injury-enhanced, evoked electrical 
activity in the nerve as long as 3 months after the injury 
(Yates, Smith, Robinson, 2004). The lack of effect induced 
by the dexamethasone-loaded implant when mechanical 
allodynia was fully established is a limitation of the present 
study. The contrasting effects induced by dexamethasone 
and methylprednisolone on reversal of ongoing allodynia 
imply that these SAIDs may act on different biochemical 
pathways. Further studies are needed to compare their 
effects on neural excitability in vivo and to evaluate which 
SAID would be most suitable to be included in an implant 
aimed to induce a local effect.
The present study indicates that dexamethasone 
treatment induces peripheral antineuroinflammatory 
effect, as assessed by inhibition of NF-κB activation. 
However, as a systemic effect of dexamethasone is evident, 
we hypothesize that this steroid may also induce a central 
pronociceptive effect, as this has been demonstrated 
elsewhere (Wang et al., 2004), which may counteract, at 
least partially, the peripheral antineuroinflammatory effect 
underlying its antinociceptive activity. Dexamethasone 
may act peripherally through multiple mechanisms to 
induce the antiallodynic effect. The proinflammatory 
responses of neutrophils, macrophages, lymphocytes, and 
mast cells, which normally infiltrate into the nerve after 
injury (Okuda et al., 2006; Perkins, Tracey, 2000), can be 
suppressed by dexamethasone (Clatworthy et al., 1995). 
Furthermore, Schwann cells are activated after CCI, and 
their production of cytokines and chemokines is inhibited 
by dexamethasone in vitro (Rutkowski et al., 1999), 
though in vivo evidence seems to be lacking. This variety 
of cell types can release a wide array of inflammatory 
mediators which sensitize or directly activate nociceptors, 
thereby enhancing pain. Further studies are thus required 
to elucidate SAIDs’ actions on the development and 
progression of neuropathies.
The results reinforce the evidence that early 
neuroimmune interactions are essential for triggering 
mechanisms necessary for the development of long-lasting 
mechanical allodynia in neuropathic pain models, though 
additional actions on neural excitability may also be taken 
into account. Novel therapeutic interventions might be 
developed based on early suppression of inflammatory 
response that occurs shortly after a stimulus that causes 
neuropathic pain.
Although the demonstration of a systemic effect 
induced by the dexamethasone implant represents another 
limitation of the present study, the results indicate that 
the use of this device may allow inducing an effect with 
lower doses and consequently greater safety. In addition, 
these results may stimulate further investigation aiming 
to develop dexamethasone-loaded implants with a better 
release profile, thus inhibiting only the local changes 
that contribute to the sensitization induced by CCI and 
avoiding systemic side effects.
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